RS50841B - Derivati pirolidina kao inhibitori ciklične aspecifične fosfodiesteraze - Google Patents
Derivati pirolidina kao inhibitori ciklične aspecifične fosfodiesterazeInfo
- Publication number
- RS50841B RS50841B YUP-480/02A YUP48002A RS50841B RS 50841 B RS50841 B RS 50841B YU P48002 A YUP48002 A YU P48002A RS 50841 B RS50841 B RS 50841B
- Authority
- RS
- Serbia
- Prior art keywords
- alkyl
- cycloalkyl
- aryl
- hydrogen
- haloalkyl
- Prior art date
Links
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 title 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 229940095074 cyclic amp Drugs 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
- 150000003235 pyrrolidines Chemical class 0.000 title 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 abstract 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 125000005275 alkylenearyl group Chemical group 0.000 abstract 1
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005347 halocycloalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- -1 polycyclic hydrocarbon Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
Abstract
Jedinjenje formule:gde jeR1 odabran od C1-6 alkil C6-16 biciklični ili policiklični ugljovodonik, aril, cikloalkil, 4-, 5-, ili 6-člani zasićen heterocikl, heteroaril, C1-4alkilenaril, C1-4alkilenOaril, C1-4alkilenheteroaril, C1-4alkilenHet, C2-4alkilenarilOaril, C2-4alkilenski premošteni alkil, C1-4alkilencikloalkil, supstituisan ili nesupstituisan propargil, supstituisan ili nesupstituisan allil, ili halocikloalkil;R2 odabran od metil, ili halo-supstituisan metil, e.g., CHF2;R3 odabran od C(=O)OR7, C(=O)R7, NHC(=O)OR7, C1-3alkilenC(=O)OR8, C1-3alkilenC(=O)R8, C(=NH)NR8R9, C(=O)-C(=O)C(=O)OR8, C1-4alkilenOR8, aril, C1-3alkilenaril, C1-3alkilenheteroaril, SO2heteroaril, Het, ili heteroaril;R4 odabran od vodonik, C1-6 alkil, haloalkil, ili cikloalkil;R5 odabran od C1-6 alkil, alkinil, haloalkil, hidroksialkil, cikloalkil, ili aril;R6 odabran od vodonik, C1-6alkil, i C(=O)R7;R odabran od C1-6 alkil ili cikloalkil, svaki po izboru supstituisan sa jednim ili više: OC(=O)R8, C(=O)OR8, OR8, NR8R9, ili SR8;R8 i R9 , isti ili različiti, odabrani su od vodonika, C1-6 alkil, cikloalkil, aril, heteroaril, C(=O)Oalkil, C(=O)-Oaril, C(=O)alkil, alkilSO2, C(=O)-C1-3alkilenaril, C(=O)OC1-4alkilenaril, C1-4alkilenaril, ili Het, ili R8 i R9 zajedno formiraju 4-člani do 7-člani prsten;R10 odabran od vodonik, alkil, haloalkil, ili cikloalkil;R 11 odabran od alkil, cikloalkil, trifluorometil, aril, aralkil, i NR8R9; injihove soli i solvati.Prijava sadrži još 77 patentnih zahteva.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/471,846 US6258833B1 (en) | 1999-12-23 | 1999-12-23 | Cyclic AMP-specific phosphodiesterase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
YU48002A YU48002A (sh) | 2005-11-28 |
RS50841B true RS50841B (sr) | 2010-08-31 |
Family
ID=23873210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YUP-480/02A RS50841B (sr) | 1999-12-23 | 2000-11-28 | Derivati pirolidina kao inhibitori ciklične aspecifične fosfodiesteraze |
Country Status (29)
Country | Link |
---|---|
US (6) | US6258833B1 (sr) |
EP (1) | EP1242400B1 (sr) |
JP (1) | JP4294903B2 (sr) |
KR (1) | KR20020063600A (sr) |
CN (1) | CN1434813A (sr) |
AT (1) | ATE325108T1 (sr) |
AU (1) | AU778543B2 (sr) |
BG (1) | BG65892B1 (sr) |
BR (1) | BRPI0016693B1 (sr) |
CA (1) | CA2395193C (sr) |
CZ (1) | CZ20022188A3 (sr) |
DE (1) | DE60027769D1 (sr) |
EA (1) | EA005686B1 (sr) |
EE (1) | EE05087B1 (sr) |
GE (1) | GEP20043384B (sr) |
HK (1) | HK1051359A1 (sr) |
HR (1) | HRP20020541B1 (sr) |
HU (1) | HUP0301113A3 (sr) |
IL (1) | IL150313A0 (sr) |
IS (1) | IS6436A (sr) |
MX (1) | MXPA02006212A (sr) |
NO (1) | NO20023008L (sr) |
PL (1) | PL202227B1 (sr) |
RS (1) | RS50841B (sr) |
SK (1) | SK287964B6 (sr) |
TR (1) | TR200400702T4 (sr) |
UA (1) | UA73964C2 (sr) |
WO (1) | WO2001047905A1 (sr) |
ZA (1) | ZA200205551B (sr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455571B1 (en) * | 1998-04-23 | 2002-09-24 | Abbott Laboratories | Inhibitors of neuraminidases |
US6258833B1 (en) * | 1999-12-23 | 2001-07-10 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
US20030022814A1 (en) * | 2000-02-29 | 2003-01-30 | Reines Scott A | Method for treating or preventing depression |
ATE546425T1 (de) * | 2000-07-03 | 2012-03-15 | Novartis Ag | Herstellung von (r)-2-alkyl-3-phenylpropionsäuren |
US6953774B2 (en) * | 2000-08-11 | 2005-10-11 | Applied Research Systems Ars Holding N.V. | Methods of inducing ovulation |
WO2002047540A2 (en) * | 2000-12-15 | 2002-06-20 | The General Hospital Corporation | Methods for inhibiting fibrosis |
US20040014099A1 (en) * | 2001-03-19 | 2004-01-22 | Decode Genetics Ehf. | Susceptibility gene for human stroke; methods of treatment |
US20030073711A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of scleroderma |
US6479493B1 (en) | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
KR20090080573A (ko) * | 2001-10-16 | 2009-07-24 | 메모리 파마슈티칼스 코포레이션 | 신경계 증후군의 치료를 위한 pde-4 억제제로서의 4-(4-알콕시-3-히드록시페닐)-2-피롤리돈 유도체 |
BRPI0117198B1 (pt) * | 2001-12-14 | 2018-03-13 | Merck Serono S.A. | Usos de composição compreendendo um inibidor seletivo de uma isoforma 4 de fosfodiesterase |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
DE10228132A1 (de) * | 2002-06-24 | 2004-01-22 | Arzneimittelwerk Dresden Gmbh | Amide cyclischer Aminosäuren als PDE 4 Inhibitoren |
SI1606261T1 (sl) | 2003-03-10 | 2010-03-31 | Nycomed Gmbh | Novi postopek za pripravo roflumilasta |
EP1613590A2 (en) * | 2003-04-16 | 2006-01-11 | Memory Pharmaceutical Corporation | 4-(3,4-disubstituted phenyl)-pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors |
BRPI0409888A (pt) * | 2003-04-18 | 2006-05-23 | Memory Pharm Corp | derivados de pirazol como inibidores de fosfodiesterase 4, composto, composição farmacêutica, método para efetuar a inibição da enzima pde4, incrementar a cognição e/ou tratar a psicose em um paciente, método para o tratamento de um paciente que tem uma doença que envolve nìveis de camp diminuìdos, método para o tratamento de um paciente que sofre de uma doença alérgica ou inflamatória e método para o tratamento de um paciente que sofre de neurodegeneração resultante de uma doença ou de um ferimento |
EP1635834A4 (en) * | 2003-06-25 | 2009-12-02 | Smithkline Beecham Corp | NEW COMPOUNDS |
CA2540061A1 (en) * | 2003-09-30 | 2005-04-14 | Merck & Co., Inc. | Phenyl pyrrolidine ether tachykinin receptor antagonists |
US20050201989A1 (en) * | 2004-02-19 | 2005-09-15 | St. Camillus Medical, Inc. | Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitors of tumor necrosis factor-alpha |
EP1732921B1 (en) * | 2004-04-08 | 2008-11-05 | Wyeth | Thioamide derivatives as progesterone receptor modulators |
CA2584317A1 (en) | 2004-10-15 | 2006-04-27 | Memory Pharmaceuticals Corporation | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
AU2005295350A1 (en) * | 2004-10-20 | 2006-04-27 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
DK1861074T3 (da) * | 2005-03-16 | 2013-07-29 | Takeda Gmbh | Smagsmaskeret doseringsform indeholdende roflumilast |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
WO2007025177A2 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
MX2008006076A (es) | 2005-11-09 | 2008-12-16 | Combinatorx Inc | Metodos, composiciones y kits para el tratamiento de condiciones medicas. |
EP1991212A1 (en) * | 2006-03-08 | 2008-11-19 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
EP2026813A2 (en) * | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
BRPI0716604A2 (pt) | 2006-09-08 | 2013-04-09 | Braincells Inc | combinaÇÕes contendo um derivado de 4-acilaminopiridina |
US20080103165A1 (en) * | 2006-09-19 | 2008-05-01 | Braincells, Inc. | Ppar mediated modulation of neurogenesis |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
TW200831497A (en) * | 2006-10-12 | 2008-08-01 | Epix Delaware Inc | Carboxamide compounds and their use |
RS52812B (sr) | 2007-08-07 | 2013-10-31 | Takeda Pharmaceutical Company Limited | Derivati pirolidin-2-ona kao modulatori androgenskih receptora |
BRPI0820701A2 (pt) | 2007-12-11 | 2015-06-16 | Cytopathfinder Inc | Composto de carboxamida e seu uso como agonistas do receptor de quimiocina |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
CN102603623A (zh) * | 2011-12-26 | 2012-07-25 | 北京赛林泰医药技术有限公司 | 制备高纯度罗氟司特的方法 |
US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
JO3264B1 (ar) * | 2013-03-13 | 2018-09-16 | Lilly Co Eli | مركبات ازيتيدينيل أوكسي فينيل بيروليدين |
WO2015112568A1 (en) * | 2014-01-24 | 2015-07-30 | Celgene Corporation | Methods for the treatment of obesity using apremilast |
ES2841308T3 (es) * | 2014-05-29 | 2021-07-08 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirrolidina novedoso y aplicación como agonista del receptor de melanocortina |
WO2016033776A1 (en) * | 2014-09-04 | 2016-03-10 | Eli Lilly And Company | Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol |
TW201625591A (zh) | 2014-09-12 | 2016-07-16 | 美國禮來大藥廠 | 吖丁啶基氧苯基吡咯啶化合物 |
WO2017072796A1 (en) | 2015-10-30 | 2017-05-04 | Council Of Scientific & Industrial Research | 2-pyridone based compounds useful as potential phosphodiesterase3a (pde3a)inhibitors and a process for the preparation thereof |
JP6392297B2 (ja) * | 2015-11-27 | 2018-09-19 | 田辺三菱製薬株式会社 | 医薬組成物 |
WO2019065954A1 (ja) | 2017-09-29 | 2019-04-04 | 田辺三菱製薬株式会社 | 光学活性ピロリジン化合物及びその製造方法 |
JP7227380B2 (ja) * | 2018-12-18 | 2023-02-21 | 武漢人福創新薬物研発中心有限公司 | フェニルピロリジン化合物及びその用途 |
CN112409333B (zh) * | 2019-08-23 | 2024-06-14 | 武汉人福创新药物研发中心有限公司 | 苯基吡咯烷类化合物 |
TW202146385A (zh) * | 2020-04-29 | 2021-12-16 | 大陸商廣東東陽光藥業有限公司 | 取代的吡咯烷類化合物及其在藥物中的應用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5821622B2 (ja) * | 1973-02-28 | 1983-05-02 | ウェルファイド株式会社 | ピロリジンメタノ−ル ノ セイゾウホウ |
JPS50108258A (sr) * | 1974-02-08 | 1975-08-26 | ||
US5665754A (en) * | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
JPH07300455A (ja) * | 1994-03-08 | 1995-11-14 | Mitsubishi Chem Corp | 3−フェニルピロリジン誘導体 |
CA2143143A1 (en) * | 1994-03-08 | 1995-09-09 | Toshihiko Tanaka | 3-phenylpyrrolidine derivatives |
US5998428A (en) | 1995-05-31 | 1999-12-07 | Smithkline Beecham Corporation | Compounds and methods for treating PDE IV-related diseases |
US5856103A (en) * | 1994-10-07 | 1999-01-05 | Board Of Regents The University Of Texas | Method for selectively ranking sequences for antisense targeting |
DE19601938A1 (de) * | 1996-01-12 | 1997-07-17 | Schering Ag | Neue Phosphodiesteraseinhibitoren |
BR9810733A (pt) * | 1997-04-04 | 2000-09-12 | Pfizer Prod Inc | Derivados de nicotinamida |
US6258833B1 (en) * | 1999-12-23 | 2001-07-10 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
-
1999
- 1999-12-23 US US09/471,846 patent/US6258833B1/en not_active Expired - Lifetime
-
2000
- 2000-11-21 US US09/717,956 patent/US6423710B1/en not_active Expired - Lifetime
- 2000-11-28 RS YUP-480/02A patent/RS50841B/sr unknown
- 2000-11-28 GE GE4860A patent/GEP20043384B/en unknown
- 2000-11-28 AT AT00987999T patent/ATE325108T1/de not_active IP Right Cessation
- 2000-11-28 EP EP00987999A patent/EP1242400B1/en not_active Expired - Lifetime
- 2000-11-28 BR BRPI0016693-6A patent/BRPI0016693B1/pt not_active IP Right Cessation
- 2000-11-28 UA UA2002065192A patent/UA73964C2/uk unknown
- 2000-11-28 WO PCT/US2000/032401 patent/WO2001047905A1/en active IP Right Grant
- 2000-11-28 MX MXPA02006212A patent/MXPA02006212A/es active IP Right Grant
- 2000-11-28 JP JP2001549376A patent/JP4294903B2/ja not_active Expired - Fee Related
- 2000-11-28 CA CA002395193A patent/CA2395193C/en not_active Expired - Fee Related
- 2000-11-28 AU AU24262/01A patent/AU778543B2/en not_active Ceased
- 2000-11-28 SK SK917-2002A patent/SK287964B6/sk not_active IP Right Cessation
- 2000-11-28 TR TR2004/00702T patent/TR200400702T4/xx unknown
- 2000-11-28 CZ CZ20022188A patent/CZ20022188A3/cs unknown
- 2000-11-28 EE EEP200200351A patent/EE05087B1/xx not_active IP Right Cessation
- 2000-11-28 PL PL355988A patent/PL202227B1/pl unknown
- 2000-11-28 DE DE60027769T patent/DE60027769D1/de not_active Expired - Lifetime
- 2000-11-28 HU HU0301113A patent/HUP0301113A3/hu unknown
- 2000-11-28 IL IL15031300A patent/IL150313A0/xx unknown
- 2000-11-28 KR KR1020027008133A patent/KR20020063600A/ko not_active Application Discontinuation
- 2000-11-28 CN CN00819096A patent/CN1434813A/zh active Pending
- 2000-11-28 EA EA200200590A patent/EA005686B1/ru not_active IP Right Cessation
-
2001
- 2001-05-02 US US09/847,424 patent/US6458787B1/en not_active Expired - Lifetime
-
2002
- 2002-05-17 US US10/151,202 patent/US6716871B2/en not_active Expired - Lifetime
- 2002-06-19 IS IS6436A patent/IS6436A/is unknown
- 2002-06-20 HR HR20020541A patent/HRP20020541B1/xx not_active IP Right Cessation
- 2002-06-21 NO NO20023008A patent/NO20023008L/no unknown
- 2002-06-24 BG BG106860A patent/BG65892B1/bg unknown
- 2002-07-11 ZA ZA200205551A patent/ZA200205551B/en unknown
-
2003
- 2003-03-19 HK HK03102027.0A patent/HK1051359A1/zh unknown
-
2004
- 2004-01-15 US US10/758,675 patent/US6998416B2/en not_active Expired - Lifetime
-
2005
- 2005-11-07 US US11/268,374 patent/US7176229B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS50841B (sr) | Derivati pirolidina kao inhibitori ciklične aspecifične fosfodiesteraze | |
TR200401413T1 (tr) | Dibenzilamin bileşikleri ve bunların farmasötik kullanımları | |
HRP20090151T3 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
MY141578A (en) | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | |
RS52397B (sr) | Derivati pirido /2,1-a/izohinolina kao dpp-iv inhibitori | |
YU48390B (sh) | Novi derivati 2-anilinopirimidina, postupak za njihovo dobijanje i sredstva za uništavanje štetočina, koja sadrže ove derivate | |
HUP0201935A2 (hu) | A SYK tirozin-protein-kináz inhibitoraiként alkalmazható purinszármazékok | |
YU36998A (sh) | Derivati supstituisane 4-hidroksi-fenilalkanske kiseline sa dejstvom agonista na ppar gama | |
MEP22008A (en) | Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
AR025975A1 (es) | Compuestos quimicos. | |
ATE316967T1 (de) | Zyklische amidderivate die cathepsin k hemmen | |
AR026351A1 (es) | Derivados de pirrol como inhibidores de la fosfodiesterasa vii | |
ES2177058T3 (es) | Compuestos eter piperidinilaminometil trifluorometil ciclicos como antagonistas de la sustancia p. | |
HUP0402244A2 (hu) | Heterociklusos glicinamid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
ES2058531T3 (es) | Amidas de mercapto-fenilalcanoilaminoacidos, su preparacion y su uso como inhibidores de colagenasa. | |
NO992897L (no) | Nye oksocykliske urinstoffer som er nyttige som antiarytmiske og antifibrillatoriske midler | |
RS51126B (sr) | Postupak za pripremanje mezilata piperazin derivata | |
EP0322184A3 (en) | N-(2-alkyl-3-mercapto-1,5-di-oxoalkyl)glycinamide derivatives and their use as collagenase inhibitors | |
DE60209806D1 (de) | 2-amino-thiazolinderivate und ihre verwendung als hemmstoffe der induzierbaren no-synthase | |
YU13899A (sh) | Pirolidinil i pirolinil etilaminska jedinjenja kao kapa agonisti | |
BR0307424A (pt) | Compostos heterocìclicos com atividade inibidora de elastase e seus intermediários | |
NO940498L (no) | Nye cykliske ureaforbindelser som er nyttige som antiarytmiske og antifibrillatoriske midler | |
ES442442A1 (es) | Procedimiento para preparar derivados del oxatiinno (1,4) (2,3-c) pirrol. | |
AR039175A1 (es) | Derivados de morfolina, antagonistas de ccr3 | |
YU49090B (sh) | Postupak za dobijanje ariloksipropanol amina |